FFPE (formalin-fixed, paraffin-embedded) tissue is preserved by formalin fixation and embedded in paraffin for sectioning and storage. Fresh frozen tissue is frozen without chemical fixation, usually soon after collection, to preserve molecular material for analysis. An FFPE tissue biobank can support histopathology and many validated molecular assays, while fresh frozen tissue offers advantages for assays that need less chemically modified RNA or protein. Neither format should be confused with viable tissue prepared for live-cell culture. The right choice depends on the analyte, assay protocol, and quality requirements.
Histopathology, IHC, spatial biology, archiving
NonviableRNA-seq, proteomics, multi-omics profiling
NonviableOrganoid and primary cell generation, functional assays
ViableFormalin fixation cross-links proteins and helps preserve tissue architecture, making FFPE a standard format for histopathology, immunohistochemistry (IHC), and many spatial biology assays. Blocks can be stored at room temperature for years, although molecular quality and antigen detection depend on fixation, processing, storage, and block age. Fixation and processing can fragment or chemically modify nucleic acids and mask protein epitopes. These effects require appropriate extraction, antigen retrieval, and assay validation. FFPE-compatible RNA-seq is well established; FFPE cannot support viable-cell or organoid generation because fixation kills the cells.
Fresh frozen tissue avoids formalin-induced cross-linking and is often preferred for assays that require relatively intact RNA or native molecular profiles. Quality still depends on ischemia time, freezing method, and storage; freezing can also introduce tissue artifacts. Storage is commonly at -80°C, with validated frozen transport and limits on thawing. Routine snap-freezing is not designed to preserve cell viability. Organoid and primary cell generation require viable material, which can be freshly collected tissue or tissue preserved by a validated viable cryopreservation protocol using cryoprotectants. Snap-freezing and viable cryopreservation serve different purposes.
| Format | Best for | Key limitation |
|---|---|---|
| FFPE | Histopathology, IHC, spatial biology, validated molecular assays, archiving | Fixed cells are nonviable; nucleic acids and epitopes can be altered |
| Fresh frozen | RNA-seq, proteomics, multi-omics profiling | Requires frozen storage and transport; routine snap-freezing does not preserve viability |
| Fresh (live, <24h target) | Organoid and primary cell generation, functional assays | Perishable; timing and conditions must support the intended culture |
DRL maintains over 200 FFPE tumor samples across 30+ cancer types, sourced from IRB-approved biobanks with full chain-of-custody documentation, alongside prospective procurement through a network of 33 hospitals and 18 clinics for fresh and fresh frozen material. When a study needs live tissue for organoid or primary cell work, DRL targets processing within 24 hours of surgical procurement. Clinical metadata, including treatment history, tumor profile, and relevant staging, is linked to every sample, regardless of format. Preservation and acceptance criteria should be matched to the downstream assay.
No. Formalin fixation kills cells and cross-links their components, so FFPE tissue cannot be used to establish viable organoids or primary cell cultures. Use fresh viable tissue or material preserved through a validated viable cryopreservation protocol.
The interval from removal to freezing should be minimized and controlled for the tissue and intended assay. RNA expression and labile protein signals can change before freezing, so collection, preservation times, and temperatures need to be recorded. DRL targets processing within 24 hours for live-tissue procurement; that target is not a general acceptable delay before snap-freezing tissue for molecular analysis.
Match the format to the assay. Many IHC, targeted DNA/RNA, and spatial biomarker workflows are validated for FFPE. Fresh frozen tissue may be preferable when an assay needs higher-integrity RNA, less chemically modified proteins, or broad molecular profiling. FFPE-compatible RNA-seq can also support discovery when the protocol and sample quality are suitable.
In many cases, yes. A planned procurement can allocate tissue from the same resection to both formats, provided diagnostic needs and tissue quantity allow it. Adjacent pieces may differ in tumor content or composition, so histological review remains important when comparing results across formats.
If you are unsure which format fits your assay, tell us what you are measuring so that preservation can be planned before collection.
Start a conversation with DRL's team